{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:29:18Z","timestamp":1792027758219,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,8,17]],"date-time":"2014-08-17T00:00:00Z","timestamp":1408233600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1038\/nm.3645","type":"journal-article","created":{"date-parts":[[2014,8,17]],"date-time":"2014-08-17T16:46:22Z","timestamp":1408293982000},"page":"1043-1049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":900,"title":["Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition"],"prefix":"10.1038","volume":"20","author":[{"given":"Luzhou","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenpeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Jabbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E","family":"Cerise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire A","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijuan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivan","family":"Harel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina M","family":"DeStefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Petukhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Mackay-Wiggan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M","family":"Christiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Clynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,17]]},"reference":[{"key":"BFnm3645_CR1","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMra1103442","volume":"366","author":"A Gilhar","year":"2012","unstructured":"Gilhar, A., Etzioni, A. & Paus, R. Alopecia areata. N. Engl. J. Med. 366, 1515\u20131525 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3645_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature09114","volume":"466","author":"L Petukhova","year":"2010","unstructured":"Petukhova, L. et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 466, 113\u2013117 (2010).","journal-title":"Nature"},{"key":"BFnm3645_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1172\/JCI551","volume":"101","author":"A Gilhar","year":"1998","unstructured":"Gilhar, A., Ullmann, Y., Berkutzki, T., Assy, B. & Kalish, R.S. Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J. Clin. Invest. 101, 62\u201367 (1998).","journal-title":"J. Clin. Invest."},{"key":"BFnm3645_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.0022-202X.2005.23692.x","volume":"124","author":"KJ McElwee","year":"2005","unstructured":"McElwee, K.J. et al. Transfer of CD8+ cells induces localized hair loss whereas CD4+\/CD25\u2212 cells promote systemic alopecia areata and CD4+\/CD25+cells blockade disease onset in the C3H\/HeJ mouse model. J. Invest. Dermatol. 124, 947\u2013957 (2005).","journal-title":"J. Invest. Dermatol."},{"key":"BFnm3645_CR5","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/sj.jid.5701183","volume":"128","author":"T Ito","year":"2008","unstructured":"Ito, T. et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J. Invest. Dermatol. 128, 1196\u20131206 (2008).","journal-title":"J. Invest. Dermatol."},{"key":"BFnm3645_CR6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/1523-1747.ep12382416","volume":"102","author":"JP Sundberg","year":"1994","unstructured":"Sundberg, J.P., Cordy, W.R. & King, L.E. Jr. Alopecia areata in aging C3H\/HeJ mice. J. Invest. Dermatol. 102, 847\u2013856 (1994).","journal-title":"J. Invest. Dermatol."},{"key":"BFnm3645_CR7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1046\/j.1523-1747.1998.00380.x","volume":"111","author":"KJ McElwee","year":"1998","unstructured":"McElwee, K.J., Boggess, D., King, L.E. Jr. & Sundberg, J.P. Experimental induction of alopecia areata-like hair loss in C3H\/HeJ mice using full-thickness skin grafts. J. Invest. Dermatol. 111, 797\u2013803 (1998).","journal-title":"J. Invest. Dermatol."},{"key":"BFnm3645_CR8","doi-asserted-by":"publisher","first-page":"e94260","DOI":"10.1371\/journal.pone.0094260","volume":"9","author":"M Bertolini","year":"2014","unstructured":"Bertolini, M. et al. Abnormal interactions between perifollicular mast cells and CD8+ T cells may contribute to the pathogenesis of alopecia areata. PLoS ONE 9, e94260 (2014).","journal-title":"PLoS ONE"},{"key":"BFnm3645_CR9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/ni.2536","volume":"14","author":"JA Best","year":"2013","unstructured":"Best, J.A. et al. Transcriptional insights into the CD8+ T cell response to infection and memory T cell formation. Nat. Immunol. 14, 404\u2013412 (2013).","journal-title":"Nat. Immunol."},{"key":"BFnm3645_CR10","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ni.2395","volume":"13","author":"NA Bezman","year":"2012","unstructured":"Bezman, N.A. et al. Molecular definition of the identity and activation of natural killer cells. Nat. Immunol. 13, 1000\u20131009 (2012).","journal-title":"Nat. Immunol."},{"key":"BFnm3645_CR11","first-page":"154","volume":"12","author":"I Brajac","year":"2004","unstructured":"Brajac, I., Gruber, F., Petrovecki, M. & Malnar-Dragojevic, D. Interleukin-2 receptor \u03b1-chain expression in patients with alopecia areata. Acta Dermatovenerol. Croat. ADC 12, 154\u2013156 (2004).","journal-title":"Acta Dermatovenerol. Croat. ADC"},{"key":"BFnm3645_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood.V97.1.14","volume":"97","author":"TA Fehniger","year":"2001","unstructured":"Fehniger, T.A. & Caligiuri, M.A. Interleukin 15: biology and relevance to human disease. Blood 97, 14\u201332 (2001).","journal-title":"Blood"},{"key":"BFnm3645_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1006\/cimm.1996.0293","volume":"174","author":"W Ye","year":"1996","unstructured":"Ye, W., Young, J.D. & Liu, C.C. Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes. Cell. Immunol. 174, 54\u201362 (1996).","journal-title":"Cell. Immunol."},{"key":"BFnm3645_CR14","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1084\/jem.20060028","volume":"203","author":"B Meresse","year":"2006","unstructured":"Meresse, B. et al. Reprogramming of CTLs into natural killer-like cells in celiac disease. J. Exp. Med. 203, 1343\u20131355 (2006).","journal-title":"J. Exp. Med."},{"key":"BFnm3645_CR15","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.1002188","volume":"185","author":"P Saikali","year":"2010","unstructured":"Saikali, P., Antel, J.P., Pittet, C.L., Newcombe, J. & Arbour, N. Contribution of astrocyte-derived IL-15 to CD8 T cell effector functions in multiple sclerosis. J. Immunol. 185, 5693\u20135703 (2010).","journal-title":"J. Immunol."},{"key":"BFnm3645_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.immuni.2004.06.020","volume":"21","author":"B Meresse","year":"2004","unstructured":"Meresse, B. et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21, 357\u2013366 (2004).","journal-title":"Immunity"},{"key":"BFnm3645_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1365-2133.2006.07377.x","volume":"155","author":"P Freyschmidt-Paul","year":"2006","unstructured":"Freyschmidt-Paul, P. et al. Interferon-\u03b3-deficient mice are resistant to the development of alopecia areata. Br. J. Dermatol. 155, 515\u2013521 (2006).","journal-title":"Br. J. Dermatol."},{"key":"BFnm3645_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.0022-202X.2004.23580.x","volume":"124","author":"A Gilhar","year":"2005","unstructured":"Gilhar, A., Kam, Y., Assy, B. & Kalish, R.S. Alopecia areata induced in C3H\/HeJ mice by interferon-\u03b3: evidence for loss of immune privilege. J. Invest. Dermatol. 124, 288\u2013289 (2005).","journal-title":"J. Invest. Dermatol."},{"key":"BFnm3645_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/j.0022-202X.2005.23888.x","volume":"125","author":"P Freyschmidt-Paul","year":"2005","unstructured":"Freyschmidt-Paul, P. et al. Reduced expression of interleukin-2 decreases the frequency of alopecia areata onset in C3H\/HeJ mice. J. Invest. Dermatol. 125, 945\u2013951 (2005).","journal-title":"J. Invest. Dermatol."},{"issue":"suppl. 2","key":"BFnm3645_CR20","doi-asserted-by":"publisher","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72","author":"JJ O'Shea","year":"2013","unstructured":"O'Shea, J.J., Kontzias, A., Yamaoka, K., Tanaka, Y. & Laurence, A. Janus kinase inhibitors in autoimmune diseases. Ann. Rheum. Dis. 72 (suppl. 2), ii111\u2013ii115 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnm3645_CR21","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama, A. et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109\u20133117 (2010).","journal-title":"Blood"},{"key":"BFnm3645_CR22","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi, K. et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186, 4234\u20134243 (2011).","journal-title":"J. Immunol."},{"key":"BFnm3645_CR23","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1093\/bioinformatics\/btg307","volume":"19","author":"GS Eichler","year":"2003","unstructured":"Eichler, G.S., Huang, S. & Ingber, D.E. Gene Expression Dynamics Inspector (GEDI): for integrative analysis of expression profiles. Bioinformatics 19, 2321\u20132322 (2003).","journal-title":"Bioinformatics"},{"key":"BFnm3645_CR24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek, S. et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363, 1117\u20131127 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3645_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787\u2013798 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3645_CR26","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","volume":"67","author":"N Punwani","year":"2012","unstructured":"Punwani, N. et al. Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis. J. Am. Acad. Dermatol. 67, 658\u2013664 (2012).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnm3645_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.it.2004.09.014","volume":"26","author":"R Paus","year":"2005","unstructured":"Paus, R., Nickoloff, B.J. & Ito, T.A. A 'hairy' privilege. Trends Immunol. 26, 32\u201340 (2005).","journal-title":"Trends Immunol."},{"key":"BFnm3645_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nri1901","volume":"6","author":"TA Waldmann","year":"2006","unstructured":"Waldmann, T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6, 595\u2013601 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnm3645_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrd3571","volume":"10","author":"E Dolgin","year":"2011","unstructured":"Dolgin, E. Companies hope for kinase inhibitor JAKpot. Nat. Rev. Drug Discov. 10, 717\u2013718 (2011).","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm.3645.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.3645","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.3645.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:47:08Z","timestamp":1684435628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.3645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,17]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["BFnm3645"],"URL":"https:\/\/doi.org\/10.1038\/nm.3645","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718535351.793500575","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718535351.793499472","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718535351.793499299","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718535351.793499708","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718535351.793498981","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,17]]},"assertion":[{"value":"22 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Columbia University has filed for intellectual property protection on the treatment of AA with small-molecule JAK inhibitors (PCT\/US2011\/059029 and PCT\/US2013\/034688).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}